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Background The effectiveness of post-deployment screening for mental disorders has never been 
assessed in a randomised controlled trial (RCT). The primary aim of this study was to assess whether 
post-deployment screening for posttraumatic stress disorder (PTSD), depression, anxiety and/or 
alcohol misuse was effective. Screening was defined as the presumptive identification of 
unrecognised disorder using tests to distinguish those who probably have a disorder from those who 
probably do not so that those with a probable disorder can be referred for diagnosis and treatment. 
Effectiveness was assessed by the odds ratios at follow up for the main outcomes between those 
receiving tailored advice and those receiving only general advice, and the secondary aim was to 
assess whether tailored advice following assessment increased help-seeking behaviour in those with 
a probable mental disorder. 
Methods The study was a cluster RCT conducted among military personnel following deployment to 
Afghanistan. Initial assessment took place 6 to 12 weeks post-deployment, follow-up measures were 
obtained 10 to 24 months later. Follow-up measures were PTSD checklist civilian version, Patient 
Health Questionnaire-9, Generalized Anxiety Disorder questionnaire, Alcohol Use Disorder 
Identification Test (AUDIT) and self-reported help-seeking from clinical and welfare providers 
comparing those receiving tailored advice and those receiving only general advice.  
Findings 274 platoons (6,350 subjects) were randomly allocated to the screening arm and 160 
platoons (3,840 subjects) to the control arm. 5,577 (87·8%) received the screening, of which 3,996 
(62·9%) completed follow-up, while 3,149 (82·0%), were controls of which 2,369 (61·7%) completed 
follow-up. 1,958 (35·1%) of those in the screening arm declined to see the tailored advice; but those 
with PTSD, anxiety or depression (approximately 83%) were more likely to view the advice. At 
follow-up, there were no significant differences for PTSD (OR 0·92, 95% CI 0·75- 1·14), depression 
and/or anxiety (OR 0·91, 95% CI 0·71- 1·16), alcohol misuse (OR 0·88, 95% CI 0·73- 1·06) or seeking 
support for mental disorders (OR 0·92, 95% CI 0·78- 1·08).  
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Interpretation Post-deployment screening for mental disorders based on tailored advice was not 
effective at reducing prevalence of mental health disorders, nor did it increase help-seeking rates. 
Countries that have implemented post-deployment screening programmes for mental disorders 
should consider monitoring the outcomes of their programmes.  
Funding The US Congressionally Directed Medical Research Programs Award Number W81XWH-10-
1-0881. 
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The United Kingdom (UK) deployed in excess of 220,550 personnel to the Afghanistan and Iraq 
conflicts between 2001 and 31 March 2014,1 approximately 37% of whom deployed more than 
once.2 Fatalities and seriously injured personnel from those conflicts amounted to 632 and 838 
respectively,3, 4 similar rates (but not absolute numbers ) to those experienced by United States 
forces. The intensity of operations and the high proportion of the total strength of the UK Armed 
Forces (UK AF) that participated in these conflicts created an expectation that the conflict would 
have a substantial impact on the mental health of UK service personnel. Although higher rates were 
observed in those in direct combat roles, the prevalence of PTSD, psychological distress and alcohol 
misuse among regular UK personnel deployed to Iraq and Afghanistan was four percent, 20% and 
16% respectively,5 not dissimilar to rates found among those who did not deploy to Iraq and/or 
Afghanistan.5, 6 But even though the rates are not as high as some anticipated, the absolute numbers 
are still substantial. Mental health screening is one way to address these problems. Several countries 
have done so implementing a mental health screening programme on return from deployment, the 
most sensible time to do so.  
Screening uses relatively simple tests which are not intended to be diagnostic to distinguish between 
those who may or may not have a condition in order to provide early diagnosis and treatment for 
those who may have a disorder so that longer-term negative health consequences can be mitigated. 
The US military has implemented a post-deployment screening programme for mental disorders 
with repeated assessments in the 30 months following the end of deployment.7 Canada, Australia 
and the Netherlands also utilise post-deployment screening procedures for mental disorders. 8, 9 The 
drive to implement mental health screening arises from findings that at least half of military 
personnel with probable mental disorder do not seek help,10,11 that many seek help too late,12  that 
chronicity is associated with slower recovery,7 that screening may help to overcome stigma 
associated with mental disorder,13 and finally, that government supported screening programmes 
demonstrate a commitment to providing preventive services to military personnel returning from 
deployment.14 However, to date, no randomised control trials (RCTs) have assessed the effectiveness 
5 
 
of screening or its impact of on help-seeking behaviour. As the UK has not mandated such a 
programme we had the opportunity to conduct a RCT of screening, which would not have been 
possible in countries where screening was already national policy, in part because of the potential 
ethical and public opinion impact of discontinuing an established programme. To date, only 
observational studies have measured the impact of post-deployment screening; such studies 
showed that only a subset of those screening positive for mental disorders sought and received an 
adequate number of therapy or treatment sessions 15. Studies lacking a randomisation and control 
element cannot answer the key questions regarding the effectiveness or its impact on help-seeking.  
The primary aim of this study was to assess whether offering tailored help-seeking advice following 
assessment for possible PTSD, depression, anxiety and alcohol misuse was effective in reducing 
prevalence. The secondary aims were whether post-deployment screening followed by tailored 
advice to seek help from welfare or medical sources for those with mental health symptoms would 
modify help-seeking behaviour and/or medication usage. We also assessed screening for PTSD (and 
other mental health problems) reduces the prevalence of post-concussion symptoms (PCS) following 
mild traumatic brain injury (mTBI) and finally whether there was a difference in subjective functional 
impairment between the screening and the control arm participants.  
Methods 
Trial design, participants and procedures 
A cluster randomised controlled trial (cRCT) was designed. We named it the Post Operational 
Screening Trial, or POST for short (registered number ISRCTN19965528). Following seven months 
preparation and piloting, the initial assessment of personnel occurred between November 2011 and 
February 2013. Follow-up took place between November 2012 and October 2014. We followed the 
latest Consolidated Standards of Reporting Trial (CONSORT) guidelines available at the time of study 
design. The cluster unit of randomisation was the platoon (usually comprising 15 to 35 service 
personnel). There were two arms: the screening group, which was offered tailored help-seeking 
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advice following an offline computerised self-administered assessment for mental disorders, based 
upon the test results for PTSD, depression, anxiety and alcohol misuse; and a control group which 
completed the same self-administered questionnaire as the intervention group, but received only 
general mental health advice. Only platoon members who had recently returned from deployment 
in Afghanistan at the time of assessment were included. The exclusions were members of platoons 
who did not deploy, those who deployed but moved to another location before randomisation, 
reserve personnel (mobilised specifically for the operation) and platoons which were formed 
specifically for deployment and had dispersed upon return home.  
Participants received written and oral explanations about the study on the day of baseline 
assessment and were free to withdraw consent at any time during the study. Consent to follow up 
was requested from all participants. We used Zelen’s design,16 which required that each individual in 
the screening group should give positive consent to see the tailored advice related to their mental 
health status, but not those receiving general advice in the control group. This was deemed 
necessary by an Ethics Committee who wanted participants in the screening arm to have the option 
of whether or not to receive tailored advice. Zelen’s design allows for the unwillingness to receive 
personal advice or management without introducing bias or attrition that would arise by requesting 
consent prior to assessment in the screening arm, especially when a cluster design is used. It also 
allows for carrying out a sensitivity analysis on the possible effect of unwillingness to receive tailored 
advice. Only Royal Marines and Army personnel were included in this study. The advice, specific or 
general, appeared at the end of the mental ill-health screening procedure, and a letter reiterating 
the advice was posted to everyone assessed at baseline in an envelope marked “Private and 
Confidential” within two weeks of the initial assessment (see letters in supplementary materials). 
Participants who chose not to see their tailored advice at the time of the assessment were invited to 
contact us if they had changed their minds and wanted to see the advice.  
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The baseline assessment was carried out between 6 and 12 weeks post-deployment. This was 
chosen to avoid interfering with immediate post-deployment leave and to minimise dispersion of 
personnel from the deploying platoons. The reassessment took place between 10 and 24 months 
after the initial assessment; but 3·5% of participants completed the follow-up assessment more than 
two years after initial assessment. Time variation in the completion of the assessment between the 
two arms of the study was significant due to change in randomisation ratio (see below), but adjusted 
for in the analysis as explained in the statistical analysis section. Three modes of administration of 
identical questionnaires were used in the follow-up assessment: an offline questionnaire on a laptop 
as used in the baseline assessment for those who were still in their original platoons and in their 
base on the day of the follow-up visit; an online version uploaded to a secure server; and a hard 
copy questionnaire that was used for those who did not have access to the electronic versions or 
were unwilling to use them. This multi-method approach was necessary because a large percentage 
of participants had changed platoons, were unavailable on the day of the follow-up visit to the base, 
or had left the Armed Forces (AF) between assessments. Members of the selected platoon were 
invited to participate regardless of the length of deployment and included those who returned early 
due to injury or illness. All those previously randomised were included in the follow-up stage 
regardless of whether they had participated in the initial assessment or not and including those who 
had left the UK AF for any reason since screening.  
Masking procedure 
The Mental Health and Neurosciences Clinical Trial Unit (MH&N CTU) at King’s College London 
carried out the randomisation. They had no knowledge of the platoons other than the numeric 
identification provided by the fieldworkers preparing the visits to the bases at the time of 
randomisation. 45 laptops were preloaded with the screening (tailored advice) and control (general 
advice) questionnaires. Fieldworkers knew whether the platoon in the room would be allocated to 
the intervention or control groups, as they had to set up the appropriate offline version of the 
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questionnaire for each group. The person analysing the data (HB) but not the statistician (MK) or 
principal investigators knew the allocation of platoons at the time of analysis.  
Measures at baseline 
First stage-assessment 
The initial offline assessment was a short two-stage questionnaire which included the primary 
outcome measures of posttraumatic stress disorder (PTSD), depression, generalised anxiety disorder 
(GAD) and alcohol misuse. We have previously reported that the two-stage questionnaire reduced 
resource burden without substantial loss of sensitivity for PTSD.17 For the secondary outcomes we 
included a question from the short form-36 (SF-36) to assess functional impairment18 and a modified 
version of the Brief Traumatic Brain Injury Screening schedule exploring possible symptoms 
associated with injury; these symptoms were losing consciousness, being dazed or confused, not 
remembering the injury and symptoms of concussion (e.g. headache and dizziness).19 Sex, age, rank 
and service arm were also recorded. The four item primary care PTSD (PC-PTSD) test (score range 
zero to 4)20 was used in the first stage and if two or more items were endorsed, respondents were 
directed to complete the PTSD checklist civilian version (PCL-C).21 The first two items (mood and 
anhedonia) in the Patient Health Questionnaire (PHQ-9) were used in the first stage; endorsing a 
symptom frequency of “more than half the days” or “nearly every day” for at least one item 
triggered the administration of the full PHQ-9.22 The first two items of the GAD scale were used for 
the first stage; if the participant scored three or more out of a total score of six, the full GAD scale 
was administered.23 Alcohol use was assessed using the first two items of the Alcohol Use Disorder 
Identification Test (AUDIT) modified to allow for higher alcohol consumption as extra categories.24 
Any person scoring eight or more, based on a frequency category from zero to four or more times a 
week and an eight category scale of increasing consumption, was directed to complete the full 
AUDIT questionnaire.  
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Second stage assessment 
The tailored advice consisted of one of three recommendations: First to visit a unit welfare officer 
(UWO) (padre, welfare staff or commander responsible for personnel welfare); second to visit to a 
medical officer (MO) or thirdly, that no professional support was required (an example of a tailored 
advice letter is shown in the supplementary materials). The general advice stated that there were 
many ways to get help if needed from sources such as colleagues, leaders, padres, welfare staff or 
medical centres (an example of the letter of general advice is given in the supplementary materials). 
Figure 1 provides the decision pathways to seek either primary care, welfare services or if no support 
was recommended. For the PCL-C (range 17-85) a score of 40-49 prompted advice to see an UWO 
and a score of 50 or more to consult a medical officer (MO); for the PHQ-9 (range 0- 9) endorsing 
three to five symptoms occurring more than half the days prompted advice to visit a UWO and six or 
more an MO; for the GAD (range 0- 21) a score of 10-14 prompted advice to visit a UWO and 15 or 
more to visit a MO. For the AUDIT total score (range 0- 40) a score of 20 or more generated advice to 
visit a UWO, for alcohol-related harm (range 0- 16) a score of 10 or more prompted advice to visit a 
MO, as did a score of five or more on the dependence scale (range 0-12). If a participant was a case 
for more than one outcome, the tailored advice was related to the more severe outcome. We used a 
threshold score of 40 for PTSD to minimise the false negative rate. This approach is consistent with 
the aim of screening to be a presumptive diagnosis only. It is also consistent with the distribution of 
most disorders that tend to be more common at lower levels of severity than at high levels of 
severity. This should not affect the results of the trial, as the comparisons between arms were 
carried out using the same threshold. In our study we recommended that those with a score of 40 to 
49 visit a welfare officer instead of a medical officer. A welfare officer would be in position to advise 
and help service personnel whether is advisable to see a doctor and a mental health specialist. Our 
expectation was that a consultation with a UWO may be helpful for personnel experiencing fewer 
symptoms given that UWOs are able to offer general support, and to arrange an appointment with a 
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MO if necessary. They may also be able to raise any concerns within the confidential unit welfare 
committee where personnel causing concern are regularly discussed.  
Follow-up assessment 
The follow up assessment included full versions of the PCL-C, PHQ-9, GAD-7 and AUDIT. The 
thresholds for being classified as a possible case were the same as those used in the baseline 
assessment. The item from the SF-36 assessing the impact of physical or emotional problems upon 
work or social functioning was used as a binary outcome which compared functional impairment 
occurring “all the time” or “most of the time” with lower frequency endorsements.18 Nine possible 
PCS were assessed; namely headache, dizziness, feeling tired or having low energy, trouble sleeping, 
irritability/outbursts of anger, double/blurred vision, forgetfulness, loss of concentration and ringing 
in the ears.25 The follow-up assessment included questions about the use of medical and welfare 
services in the previous 12 months, including receipt of prescriptions for antidepressants and 
hypnotics. The ‘Medical service providers’ category included MOs, GPs, mental health nurses, 
psychologists, psychiatrists, other health services professionals (nurses, physiotherapists etc.), 
Accident and Emergency departments and military social workers (who work directly with military 
mental health professionals). The ‘Welfare service’ category included unit welfare officer/teams, 
military chaplains, trauma risk management (TRiM) personnel, online help sources, Service charities 
(such as the Royal British Legion, the Soldiers, Sailors, Airmen and Families Association and Combat 
Stress) and civilian social workers; the latter are included as welfare providers, rather than medical 
support, as they may not work directly with mental health services in the same way as military social 
workers who have a dedicated mental health role. A sub–category of mental health services was 
formed including psychiatrists, psychologists, mental health nurses, and military social workers. 
Questions on pharmaceutical usage requested medication name and duration of taking anti–
depressants and/or sleeping tablets in the last 12 months. In addition, a section was provided with 
11 
 
free text fields for describing any other medications taken in the last 12 months; textual responses 
were re-categorised into the existing medication categories.  
Sample size and randomisation 
 At the protocol stage, a sample size of 6,000 personnel recruited over two operational phases was 
required to detect a decrease of 20% in the prevalence of PTSD, depression or anxiety with a power 
of 80% at a 5% level applying an inflation factor due to clustering of one percent. However, during 
the first phase of data collection, approximately 50% of respondents chose not to see the tailored 
advice. The initial protocol was therefore modified to include a third operational deployment and 
the randomisation ratio between intervention and control groups was increased from 1:1 to 2:1 for 
the second and third deployments. Thus the total sample was increased to a minimum of 9,000 
Service personnel estimated from platoon size. The modifications ensured that the sample size 
requirements were more than satisfied even at the lowest threshold of acceptability for the number 
agreeing to see the tailored advice. Randomisation was carried out on the day of baseline 
assessment by the MH&N CTU based on the list of platoons to be assessed, first selecting the 
companies (approximately 120 personnel) eligible for the study and the platoons (sub-groups of 
companies) stratified by headquarters (largely command and support roles) and fighting 
components (largely combat and combat support role). The rationale for such stratification was that 
there were more commissioned officers (COs) and senior non-commissioned officers (NCOs) in 
headquarter elements. Randomisation was carried out using stratified block randomisation with 
randomly varying block sizes of two and four. Figure 2 shows the structure of the study. The main 
analysis was carried out by intention to screen irrespective of whether or not the participant chose 
to see the tailored advice following the assessment.  
Statistical analysis 
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Statistical analyses were performed using STATA 11·2 (Statistical Software Version 11. StataCorp LP, 
College Station, TX). The main outcomes were assessed as binary variables rather than continuous 
variables; as the great majority of participants had scores well below any meaningful threshold of 
possible mental disorder, classifying them as non-cases, the majority in the "screening" arm received 
advice indicating that no welfare or medical help was required. The analyses of effectiveness of 
screening and help-seeking behaviour were carried out taking into account clustering by platoons 
and controlling for Service type (Royal Marines or Army) as a fixed covariate. The adjustment was 
needed to account for the change from 1:1 distribution of participants between the intervention and 
control arms in the first deployment to a distribution of 2:1 in subsequent deployments, as Royal 
Marines formed the majority of personnel on the first tour. Potential risk of bias in the estimated 
screening effect due to missing data (including missing due to incomplete questionnaire, missing 
outcome data at baseline and missing data due to non-response at follow-up) was handled under 
missing at random assumption by making additional adjustments for rank, age and date of 
deployment which were found to be associated with missingness or non-response; these 
adjustments also removed the apparent difference in response time between intervention arms, 
which was primarily a consequence of the change in sampling strategy between first and subsequent 
waves. We performed intention to treat analysis of available data irrespective of whether or not the 
participant chose to see the tailored advice following the assessment, using random effects logistic 
regression models implemented via the STATA command “xtmelogit”, with platoon as the clustering 
variable in unadjusted analysis with further adjustment carried out as described above. We 
performed analyses adjusting for covariates only and then performing additional adjustment for any 
mental health condition at baseline. There were 24 incomplete questionnaires for PCL-C, 35 for PHQ-
9, 34 for GAD and 33 for AUDIT. We performed linear mixed model analyses without any imputation 
of missing observations, which is appropriate under the missing at random assumption of missing 
outcome data, provided covariates associated with missing data are accounted for and the analysis 
is performed via mixed models using the maximum likelihood method.26 We compared personnel in 
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the two arms who reported at least three PCS at follow-up. We also compared any medical/welfare 
attendance and any use of the defined pharmaceutical categories with no medical/welfare 
attendance and no use of the defined pharmaceutical categories. When analysing the effect of 
viewing or not viewing the tailored advice, analysis was performed separately for those who would 
have been advised to seek help (whether medical or welfare) given their baseline scores on the 
various measures; we expected those who were advised that no help was necessary to differ from 
those advised to seek help. These analyses were performed for those advised to seek help for 
mental health reasons other than alcohol misuse alone, and were then repeated including alcohol, 
as serving personnel are is less receptive to help–seeking advice regarding alcohol use.11 The effect 
of the screening programme on total number of mental health–related visits was analysed using 
mixed–effects Poisson regression, with random effects at both cluster and observation level (to 
compensate for over-dispersion as most have zero visits).27 We also carried out sensitivity analyses 
creating five imputation sets using multiple imputation by chain equations, first for imputing missing 
covariates only, second imputing both covariates and baseline and follow-up outcomes for those 
responding at follow-up and thirdly imputing the 10,190 members in the study, irrespective of 
response at any stage. The sensitivity analysis showed similar results to those given in this paper. 
The reported analyses were decided a priori before seeing any results. 
Role of the funding source: 
The funders required that we submitted quarterly and annual reports informing them about the 
progress of the project for its duration. They also required for continuation of funding that we 
submitted an annual letter signed by the Ethics Committees which assured the funders that the 
study continued to fulfil ethical requirements. The funding body play no role in advising on the 
design of the study, data collection or interpretation of the results, and has not commented on the 
paper. The funders sent our protocol to reviewers when considering our project for funding and we 
modified the protocol following recommendations from the reviewers which were on points of 
detail. 
14 
 
Results  
Response rates and characteristics of responders 
A total of 434 platoons including 10,191 personnel were entered into the study, 274 (63·1%) in the 
intervention arm and 160 (36·9%) in the control arm (Figure 2). In the intervention group, 5,577 
(87·8%) responded compared with 3,149 (82·0%) of control group participants. 
Baseline participation was higher for tours 2 and 3 than for tour 1, but the participation rate was 
lower for those in headquarters platoons, the Royal Marines, and for NCOs and COs (Table 1). Most 
Royal Marines were part of tour 1. The response rate at follow-up was 62·9% (n=3,996) using the 
total initial sample in the screening group as the denominator, or 66·5% (n=3,708) using those 
completing the initial assessment as the denominator, in the control group the numbers were 61·7% 
(n=2,369) and 67·6% (n=2,128) respectively (Figure 2). The response rate at follow-up was higher for 
those in headquarters platoons, the Royal Marines, NCOs and COs (Table 1). Baseline mental health 
outcomes were not associated with likelihood of response at follow-up. Age of participants was 
positively related to completion of the follow-up questionnaire. Overall those in the screening arm 
responded quicker (15·1 months) than those in the control arm (15·4 months); however, as 
previously noted there was a change in the ratio of intervention to control after the first tour but no 
difference within waves of data collection. Differences between periods of data collection are 
adjusted for as explained in the statistical analysis section. 61·2% in the control arm and 58·2% in the 
intervention arm used medical services (mainly MOs and GPs) (Table 2). 15·0% and 13·9% in the 
control and intervention arms respectively used welfare services, and 13·4% and 12·4% in the 
control and intervention arms respectively used mental health services. 
Elected to see the tailored advice 
3,619 (64·9%) in the screening group chose to see the advice provided after assessment (Table 3). 
Lower ranks, younger personnel and non-cases were less likely to request to see the tailored advice. 
Higher percentages of those reporting symptoms related to PTSD (83·1% vs. 64·0%), depression or 
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GAD (84·2% vs. 64·5%) and alcohol problems (75·0% vs. 63·9%) wanted to see the specific advice 
than those who were non-cases. The difference for mTBI in comparison to non-cases was not 
significant. 
Effectiveness of tailored advice 
The odds ratios (ORs) for any of the mental health outcomes were not significant between the 
screening and the control arms, though the prevalence rates were slightly lower in the screening 
arm for each disorder category (Table 4). The 95% confidence intervals (CI) were sufficiently narrow 
to conclude that for all outcomes the slight decrease of prevalence in the intervention group was 
unlikely to represent an impact of the intervention. Exclusion of those without baseline information 
and adjustment for outcome at baseline did not change the results. The assessment of PCS between 
the two arms of the trial in those with a possible mTBI at baseline was not significant, but the 
statistical power for inference of this analysis was low. 
The effect of screening on help-seeking behaviour  
There was no significant difference in accessing health providers between the trial arms (Table 5). 
No significant difference in mental healthcare usage was found despite this being the primary source 
of psychological help recommended by the intervention, and there were no differences in 
pharmaceutical usage between trial arms.  
Sensitivity analysis of the impact of the intervention 
Choosing to see the tailored advice was not associated with the lack of effectiveness of screening for 
any of the outcomes (Table 6). The two adjusted analyses, one excluding baseline outcomes and the 
other including baseline outcomes, were similar.  
Among those who would not have been directed to seek help based on mental health outcomes at 
baseline, the OR of help–seeking in the intervention arm compared to the control arm was similar 
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irrespective of whether the individual chose to view the tailored advice or not (Table 7). Among 
those who would have been advised to seek help, those who chose not to view the tailored advice 
were less likely to seek help than those in the control arm, but the reverse was not observed; those 
who chose to see the tailored advice were no different on their rates of help-seeking from those in 
the control arm (Table 7). In terms of pharmaceuticals, there were no significant differences for 
antidepressants or sleeping tablets, irrespective of the form of advice that would have been received 
(Table 7). 
Mental health status at follow-up was unrelated to screening and the largest group at follow up, 
excluding non-cases was composed of cases that had developed following initial assessment 
(supplementary Table 1). We stratified the two arms into four groups: not a case, remitted, 
persistent and new case. The rationale for this analysis was to verify if the lack of effectiveness of 
screening might have been due to the heterogeneity of evolution of the conditions in the analyses. 
None of the results became statistically significant in the stratified analyses.  
Of those qualifying as probable mental health cases (PTSD, depression and/or anxiety) at baseline, 
45 (35·7%) in the control arm and 69 (33·3%) in the intervention arm had sought help from a mental 
health provider in the last 12 months (OR 0·95, 95% CI 0·59-1·54, p=0·849). Of those qualifying as 
cases at follow–up, 105 (35·5%) of those in the control arm and 141 (28·7%) of those in the 
intervention arm had sought mental healthcare in the last 12 months (OR 0·82, 95% CI 0·59-1·14, 
p=0·241). Of those seeking help from mental health services in the previous 12 months, 69 (14·7%) 
in the screening arm and 45 (15·9%) in the control arm were cases of mental health disorder at 
baseline (OR 0.97, 95% CI 0·64-1·48, p = 0.899), and 141 (28·4%) in the intervention arm and 105 
(33·0%) in the control arm were cases at follow–up (OR 0·87, 95% CI 0·60-1·25, p = 0·446). None of 
the differences between trial arms were significant. Mental health service help–seeking rates were 
consistently lower in those with alcohol misuse- 90 (18·2%) at baseline and 163 (21·7%) among cases 
at follow–up.  
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We carried out analysis based on continuous scales of the outcome variables to assess effectiveness 
of screening, but none of the assessments were significant (Supplementary Table 2). 
As shown in the Tables 3, 4 and 5 there was no evidence that anxiety or stress were associated with 
the tailored advice. We did not assess whether the tools used in the study over-diagnosed mental 
disorders.  
Discussion 
The main finding of this cRCT is that screening for mental disorder in UK military personnel and the 
provision of tailored help-seeking advice between 6 and 12 weeks after return from deployment is 
ineffective in decreasing the prevalence of PTSD, depression, anxiety and alcohol misuse over a 
period of 10 to 24 months. This study also demonstrated that tailored help–seeking advice linked to 
the results of mental disorder screening procedures, including potential alcohol misuse, did not 
influence subsequent help–seeking behaviour. Approximately a third of the participants in the 
screening arm did not want to see the tailored advice offered on-screen following completion of the 
baseline assessment; this group was less likely to access healthcare. Those who chose to see the 
help-seeking advice did not seek help more frequently than personnel in the control arm. Those who 
reported symptoms of mental disorders were more interested in seeing their advice than those who 
did not. 
This is the first RCT to assess the effectiveness of post-deployment mental disorder screening in the 
Armed Forces anywhere in the world. We found no evidence to support that informing someone 
that they were experiencing mental health disorder symptoms promoted help-seeking from mental 
healthcare providers. Only around a third of those with symptoms of mental disorder at baseline had 
sought help from a mental health provider in the 12 months during the follow–up period. 
In the following discussion we refer mostly to the US literature because is the largest, best 
developed and most researched programme. We have previously demonstrated that pre-
deployment screening in UK service personnel did not lead to an increase in seeking health care and 
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that the prediction of subsequent psychiatric morbidity including PTSD was modest.28, 29 A US study 
indirectly suggested that screening did not promote help-seeking behaviour among personnel with 
mental disorders.30 On the other hand a further US study has shown that pre-deployment review of 
those who are already being treated for a mental disorder may have an impact on the prevalence of 
PTSD in deployed US military personnel by either debarring them from deployment or by providing 
ongoing monitoring for those already receiving health-care.31 In the UK AF pre-deployment review is 
already practiced in those already receiving treatment for mental disorders. Both of these are very 
different to post-deployment screening which seeks to identify personnel with a possible mental 
disorder who have not sought mental healthcare.  
An unexpected finding in this study was that a third of the participants in the screening arm decided 
not to receive tailored advice about help-seeking based upon screening outcomes. This was more 
common in younger groups and among lower ranks, both of which are risk factors for mental 
disorders.5 However, only 15% among those with a score indicative of a mental disorder declined to 
see the tailored advice, with the exception of alcohol misuse (25%). The lack of interest in viewing 
the tailored advice shown by some UK service personnel occurred despite the vast majority receiving 
a homecoming briefing upon leaving the operational area; the briefing detailed symptom 
recognition in oneself and others, and how to access potential sources of mental health support if 
required. The unwillingness to see the tailored advice might be due to lack of interest, mistrust of 
health services, fear of receiving bad news and a conviction that mental health issues are not 
personally relevant.32, 33 
One of the criteria for introducing screening for a condition is that the natural history of the 
condition should be adequately understood. Screening may not work for PTSD in particular because 
of the diversity of trajectories of the condition over time,34, 35 even over a short period.36 
Approximately half of those who were cases at the screening stage had remitted at follow-up and 
the majority who were cases at follow-up did not have symptoms at baseline, consistent with our 
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previous results on PTSD. 37 Thus persistent PTSD symptoms are characteristic of a minority in this 
and other populations and those with a tendency to chronicity are not distinguished from the rest in 
a screening programme.  
In our study symptoms of mental disorder levels following intervention in the tailored advice group 
were marginally less frequent for all outcomes, but not significantly so compared to the control arm. 
One can speculate that this might suggest that screening could potentially be effective in settings 
with a higher prevalence of PTSD such as the US military,10, 12, 30 but, of course caution is necessary 
when extrapolating from non-significant differences, especially in a trial as large as ours. The current 
US screening programme also differs from what was tested in this trial in a number of ways. For 
example, since 2012 the US screening programme includes several opportunities for assessment of 
personnel during the post-deployment period.7 These were introduced after the start of this cRCT in 
2011. The US screening programme for most of the duration of the Iraq and Afghanistan conflict 
assessed personnel between 90 and 180 days post-deployment, which would overlap with the 90 
days post-deployment period upper limit used in this study. The US programme also requires a 
mandatory face-to-face interview with a trained professional who will review the screening results. 
This approach would increase the number of cases with a suspected mental disorder starting 
treatment, but it could also include a high percentage of service personnel with short duration PTSD 
who may not need treatment, and despite receiving face-to-face advice some individuals may be 
reluctant to follow the advice. There is also a risk that, knowing that they would have a face-to-face 
interview if a test suggested a possible mental disorder, personnel may be more inclined to modify 
responses to questions in the direction of better health. This is supported by a US report that a lack 
of anonymity in a questionnaire (which of course must be the case in a practical programme) 
markedly decreases the reported prevalence of PTSD and depression.38 Our study tested both a 
version of the US programme in place before 2012 (but without the mandatory face-to-face 
interview), as well as the most likely way a UK screening programme would have been introduced, 
not least because there were not and still are not sufficient UK personnel or resources to employ so 
20 
 
many health professionals at an early stage. But even if such resources were to be made available in 
future, a doubtful prospect, we are sceptical of an approach that adds an element of compulsion to 
a screening programme as such an approach may not be well received for many reasons, including 
privacy, fears related to impeded career progression, reduced military professional standing and a 
desire to deal with the problem without external help. 
 We understand that others may argue that a more resource intensive screening programme 
including repeated assessments over time and face-to-face interviews following each assessment 
would give results different to those presented in this cRCT. This could only be confirmed in a new 
RCT, but in the absence of such we would point out that US studies have already shown that 
screening identifies far fewer personnel who subsequently seek help for mental disorders than other 
modalities such as primary care referral, chain of command directed referrals and self-referrals,12, 15 
and confirm that a large percentage of those identified by screening do not seek help.11, 12 A recent 
US study has shown that 75% of those referred for further mental health reasons contacted health 
providers, but 40% subsequently attended only one or two therapy sessions.15 In another study it 
has been shown that 60% of personnel either failed to begin treatment or subsequently received an 
inadequate course of treatment.39  
A further point to consider is that there are only a limited number of studies assessing efficacy of 
psychotherapy and treatment among military personnel, most of them in ex-military personnel, and 
the effect sizes between studies vary from negligible to strong effects. 40 41 Many of the studies 
carried out to assess the efficacy of psychotherapy in the management of PTSD in clinical settings 
have limitations because they are observational studies rather than RCTs, comparison groups with a 
group receiving psychotherapy are made up with patients in a waiting list or being treated as usual, 
or are RCTs designed to compare two types of psychotherapy not including a true control group or 
are not analysed as intention to treat.42, 43 No RCTs has been carried out to assess the efficacy of 
management of the outcomes in this study in the UK military. Even if they were highly efficacious 
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there are several difficulties that need solving such as barriers to seeking care, patients’ willingness 
to adhere to the recommended sessions of psychotherapy and services that are properly staffed and 
organized to cope with a screening programmes for mental disorders. However, it is worth 
mentioning that in our study tailored advice did not impact upon health-seeking behaviour. 
We used a high threshold for defining alcohol misuse. The rationale was that the prevalence of 
alcohol misuse in the UK AF is high,5 and those misusing alcohol are less likely to acknowledge 
functional impairment and a health problem unless they also have a mood disorder or PTSD.11 Even 
with this increased threshold, alcohol misuse was a major contributor to mental disorder in our 
study. 
We assessed mTBI at baseline, but we did not offer tailored advice related to this event. In most 
studies PTSD is strongly associated with mTBI.36, 44 The contention was that if screening for PTSD and 
other mental disorders was effective it should also decrease the number of PCS symptoms in those 
with mTBI. However, the screening programme was not effective in reducing the prevalence of any 
of the mental health outcomes, so the likelihood of an effect of the programme upon PCS was low.  
There was no evidence that anxiety or stress were associated with the tailored advice in our study. 
We did not assess whether the questionnaires used in the study over-diagnosed mental disorders or 
led to unnecessary investigations, but all measures have been comprehensively validated. We 
acknowledge that by choosing a high threshold for identifying alcohol misuse we may have given a 
false sense of security to service personnel with a hazardous drinking pattern or a high intake 
drinking problem,24 but we were concerned not to give the impression that detecting alcohol misuse 
was the main purpose of this study.  
We recognise that it is usually advisable in an RCT to address the cost-effectiveness issues of the 
screening programme. We expect to report on this issue separately, as we collected information on 
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the volume of service and cost of each of the welfare and health services in relation to the use of 
services reported by the trial participants.  
Strengths and weaknesses 
The key strengths of the trial are the high response at baseline, a good response rate at follow-up, 
the high fidelity of the intervention throughout the study and the lack of differential attrition for the 
two arms of the trial, 1,868 (33·5%) in the screening arm and 1,021 (32·4%) in the control arm. 
Contamination between arms is a potential problem in RCTs, but it is less likely to occur in this cRCT 
as the unit of randomisation was platoon not individual; also the screening arm received individually 
tailored advice which was unlikely to be helpful to participants in the control group. Lack of blinding 
is always a problem in any RCT studies, but the purpose of this intervention was to modify behaviour 
in the screening arm and it is unlikely that lack of blinding between those who received tailored 
advice and those who received general advice would have influenced their responses at the 
reassessment stage of the study, on average a year later than the tailored advice was given.  
Anonymity is unachievable in any screening programme, as its aim is to identify individuals with a 
suspected mental disorder. Some researchers may criticise a study design in which individuals can 
opt not to see the tailored advice. However, in any RCT, consent must be given by participants to 
receive an intervention even if the intervention is seemingly not harmful. Zelen’s design avoids 
selection bias by randomisation before consent. Our approach both minimised participation losses, 
and allowed us to account for unwillingness to receive tailored advice. Questions regarding help–
seeking did not specify the problem for which help was sought. This was necessary in order to 
capture maximum information regarding mental health problems and sources of help, and for 
practical reasons, as those in the control group were given general information not mentioning 
possible diagnosis of any mental disorder. This does not affect the interpretation of the results, as 
this was a pragmatic trial in which the main purpose was to assess whether screening in the military 
would work in a real world context. We relied on self-report at follow-up to obtain data on use of 
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services and pharmaceuticals. We did not ask about what diagnosis might have been made by the 
providers, since it would have been inconsistent, preferring instead to base diagnosis from the self-
reported assessments. It is possible that there may be recall bias at work, including misclassification 
of help sources, and also unwillingness to report or misremembering events, but there is no reason 
to suspect biased reporting between trial arms. The small number of medication users limits the 
statistical power to properly evaluate any differences. We had minor errors with the randomisation 
procedure whereby a small number of participants (less than 50) were assessed with a different 
platoon and received the wrong questionnaire schedule. These participants were included in the 
intention to treat arm for analysis. We made a mistake in the algorithm to identify cases of 
depression in the offline tool at baseline. We identified those with a score of six positive responses 
instead of five; as a consequence, 16 cases were directed to informal care when their PHQ-9 
responses should have caused them to be directed to primary care. 
Implications 
This study does not support the introduction of post-deployment screening for mental disorders in 
the UK AF. Tailored advice offered in a post-deployment screening trial for mental disorders had no 
significant effect upon help-seeking behaviour and is ineffective. Possible explanations for the 
ineffectiveness of post-deployment screening may be related to a number of factors including the 
heterogeneity of evolution of mental disorders over time,34, 36 possible lack of interest in engaging 
with services in a proportion of cases15 and potential unwillingness to continue treatment among 
those who engage with services.12, 15 Previous research further suggests that between one third and 
half of treated personnel may not demonstrate meaningful symptom improvement and that those 
who improve remain above thresholds following trauma therapy.41 One possible alternative to 
screening might be to undertake case-finding by primary care staff along the lines of the US Program 
Re-Engineering of Primary Care Treatment in the military (RESPECT-Mil). RESPECT-Mil is a treatment 
model designed to screen, assess and treat active duty soldiers with depression and/or PTSD in 
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primary care. This approach follows a programme proven effective in civilians. However, a recent 
report provided unenthusiastic support for the RESPECT-Mil programme in terms of detection of 
new cases, willingness of service personnel to see health care providers and length of treatment for 
those who engaged with the care team.45  
In conclusion, this study demonstrates that the provision of tailored advice regarding help-seeking 
for mental illness embedded in a post-deployment screening programme among UK military 
personnel is ineffective in promoting help-seeking behaviour and in reducing the prevalence of 
mental disorders. Given the lack of any substantial evidence for post-deployment screening to date, 
we suggest that new programmes should not be implemented unless new evidence emerges that 
contrasts with our results. Perhaps it would now be prudent to reassess the efficiency, effectiveness 
and potentially unintended consequences of existing programmes.  
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Table 1 Characteristics of participants at baseline and follow-up, including response rates according to arm of the study. 
Variable  Control arm (n = 3,840) Intervention arm (n = 6,350) OR of response at 
follow-up for control 
arm (reference is 
intervention) 
Baseline: 
number (%) 
responding 
Follow-up: 
number (%) 
responding 
Baseline: 
number (%) 
responding 
Follow-up: 
number (%) 
responding 
All  3,149 (82·0) 2,369 (61·7) 5,577 (87·8) 3,996 (62·9) 0.95 (0·87-1·03) 
Sex Male 3,073 (88·0) 2,263 (64·8) 5,401 (91·7) 3,816 (64·8) 1.00 (0·92-1·09) 
Female 75 (86·2) 58 (66·7) 176 (95·7) 124 (67·4) 0.97 (0·56-1·66) 
Deployment Tour 1 1,227 (69·1) 1,029 (57·9) 1,412 (72·1) 1,150 (58·7) 0.97 (0·85-1·10) 
Tour 2 978 (90·4) 719 (66·5) 2,076 (93·8) 1,464 (66·2) 1.01 (0·87-1·18) 
Tour 3 944 (96·2) 621 (63·3) 2,089 (95·9) 1,382 (63·5) 0.99 (0·85-1·16) 
Platoon type Headquarters (HQ) 417 (66·6) 374 (59·7) 781 (79·7) 662 (67·6) 0.71 (0·58-0·88)** 
Non-HQ platoons 2,732 (85·0) 1,995 (62·1) 4,796 (89·3) 3,334 (62·1) 1.00 (0·91-1·09) 
Service Army 2,615 (82·7) 1,945 (61·5) 4,920 (89·2) 3,462 (62·8) 0.95 (0·87-1·04) 
Royal Marines 534 (78·7) 424 (62·4) 657 (78·8) 534 (64·0) 0.93 (0·76-1·15) 
Rank Other rank 1,579 (86·5) 1,094 (59·9) 2,742 (90·8) 1,826 (60·5) 0.98 (0·87-1·10) 
NCO 1,409 (81·0) 1,098 (63·1) 2,541 (87·7) 1,866 (64·4) 0.94 (0·83-1·07) 
CO 161 (63·6) 176 (69·6) 298 (70·8) 303 (73·0) 0.84 (0·60-1·19) 
31 
 
Age 18-24 - 876 (64·9) - 1,525 (62·5) 1.11 (0·97-1·28) 
25-29 - 624 (66·3) - 1,059 (66·4) 0.99 (0·84-1·18) 
30-34 - 353 (71·3) - 603 (69·4) 1.10 (0·86-1·40) 
35-39 - 197 (77·6) - 356 (78·8) 0.93 (0·64-1.35) 
40+ - 73 (73·0) - 153 (78·5) 0.74 (0·42-1·30) 
Baseline PCL  Not a case - 2,016 (67·5) - 3,529 (66·4) 1.05 (0·96-1·16) 
Case - 110 (67·9) - 174 (68·5) 0.97 (0·64-1·48) 
Baseline 
PHQ-9/GAD 
case 
Not a case - 2,081 (67·5) - 3,614 (66·3) 1.05 (0·96-1·16) 
Case - 45 (71·4) - 89 (73·6) 0.90 (0·46-1·77) 
Any MH 
baseline 
case 
Not a case - 2,000 (67·5) - 3,496 (66·3) 1.06 (0·96-1·16) 
Case - 126 (67·7) - 207 (69·5) 0.92 (0·62-1·37) 
Baseline 
AUDIT case 
Not a case - 1,952 (68·0) - 3,381 (66·6) 1.06 (0·97-1·17) 
Case - 174 (63·0) - 322 (64·9) 0.92 (0·68-1·25) 
Baseline Not a case  2,088 (67.7)  3,632 (66.4) 1.06 (0.96- 1.16) 
mTBI Case without LOC  28 (66.7)   50 (72.5) 0.76 (0.33- 1.74) 
 Case with LOC  10 (52.6)  21 (70.0) 0.48 (0.14- 1.57) 
* p < 0.05 
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** p < 0.01 
*** p < 0.001 
PCL= posttraumatic stress disorder checklist civilian version; PHQ-9= Patient Health Questionnaire-9; GAD-7= Generalised Anxiety Disorder-7 Scale; AUDIT= 
Alcohol Use Disorder Identification Test; MH= any mental disorder except alcohol misuse; mTBI= mild traumatic brain injury, cases included those 
symptoms associated with injury but not loss of consciousness (LOC) and those with lack of consciousness separately 
NCO= non-commissioned officers; CO= commissioned officers 
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Table 2 Help–seeking and demographic factors 
Variable  Control arm Screening arm 
n No. using 
any health 
service (%) 
No. using 
medical 
services (%) 
No. using 
welfare 
services (%) 
No. using 
MH 
services (%) 
n No. using any 
health 
service (%) 
No. using 
medical 
services (%) 
No. using 
welfare 
services (%) 
No. using 
MH services 
(%) 
All  2,369 1,500 (63·3) 1,450 (61·2) 356 (15·0) 318 (13·4) 3,996 2,410 (60·3) 2,327 (58·2) 557 (13·9) 496 (12·4) 
Sex Male 2,263 1,420 (62·8) 1,374 (60·7) 336 (14·9) 295 (13·0) 3,816 2,276 (59·6) 2,196 (57·6) 527 (13·8) 472 (12·4) 
Female 58 43 (74·1) 42 (72·4) 11 (20·0) 14 (24·1) 124 95 (76·6) 93 (75·0) 22 (17·7) 20 (16·1) 
Rank Other 
rank 
1,094 672 (61·4) 651 (59·5) 186 (17·0) 175 (16·0) 1,826 1,073 (58·8) 1,036 (56·7) 267 (14·6) 273 (15·0) 
NCO 1,098 688 (62·7) 663 (60·4) 148 (13·5) 123 (11·2) 1,866 1,136 (60·9) 1,097 (58·8) 254 (13·6) 207 (11·1) 
CO 176 139 (79·0) 135 (76·7) 22 (12·5) 19 (10·8) 303 200 (66·0) 193 (63·7) 36 (11·9) 16 (5·3) 
Service Army 1,945 1,233 (63·4) 1,192 (61·3) 304 (15·6) 286 (14·7) 3,462 2,102 (60·7) 2,033 (58·7) 491 (14·2) 440 (12·7) 
RM 424 267 (63·0) 258 (60·9) 52 (12·3) 32 (7·6) 534 308 (57·7) 294 (55·1) 66 (12·4) 56 (10·5) 
Age 18–24 876 513 (58·6) 496 (56·6) 126 (14·4) 133 (15·2) 1,525 859 (56·3) 827 (54·2) 202 (13·3) 226 (14·8) 
25–29 624 400 (64·1) 387 (62·0) 96 (15·4) 78 (12·5) 1,059 649 (61·3) 633 (59·8) 146 (13·8) 123 (11·6) 
30–34 353 234 (66·3) 225 (63·7) 57 (16·2) 42 (11·9) 603 397 (65·8) 384 (63·7) 99 (16·4) 74 (12·3) 
35–39 197 130 (66·0) 126 (64·0) 30 (15·2) 23 (11·7) 356 209 (58·7) 200 (56·2) 42 (11·8) 30 (8·4) 
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40+ 73 51 (69·9) 49 (67·1) 9 (12·3) 7 (9·6) 153 109 (71·2) 105 (68·6) 22 (14·4) 14 (9·2) 
MH services= mental health services; NCO= non-commissioned officer; CO= commissioned officer; RM= Royal Marine 
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Table 3 Characteristics of those accepting to see the specific advice in the intervention (n= 5,551) 
 
Variable  Choosing to see 
advice (%) 
OR (95% CI) 
All consenting to view 
advice 
 3,603 (64·9)  
Sex Male 3,491 (65·0) 1 
 Female 112 (63·6) 0·94 (0.69-1·29) 
Rank Other rank 1,661 (60·8) 1 
NCO 1,698 (67·3) 1·33 (1·19-1·49)*** 
CO 244 (83·0) 3·15 (2·30-4·31)*** 
Age (years) 18-24 1,527 (62·3) 1 
25-29 1,045 (65·7) 1·16 (1·02-1·33)* 
30-34 594 (68·4) 1·31 (1·11-1·55)** 
35-39 304 (67·9) 1·29 (1·04-1·60)* 
40+ 136 (70·1) 1·43 (1·04-1·96)* 
Baseline PCL case (40+) Not a case 3,393 (64·0) 1 
Case 210 (83·0) 2·74 (1·97-3·82)*** 
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Baseline PHQ-9/GAD 
case 
Not a case 3,502 (64·5) 1 
Case 101 (84·2) 2·93 (1·79-4·80)*** 
Any MH baseline case Not a case 3,357 (63·9) 1 
Case 246 (82·8) 2·73 (2·01-3·70)*** 
Baseline AUDIT case Not a case 3,233 (63·9) 1 
Case, no 
comorbidity 
287 (74·0) 1·60 (1·27- 2·03)*** 
Case, 
comorbidity 
PCL, PHQ-9 or 
GAD 
83 (78·3) 2·04 (1·28- 3·24)** 
Baseline mTBI Not a case 3,534 (64.8) 1 
 Case without  
LOC 
47 (68.1) 1.16 (0.70- 1.93) 
 Case with LOC 22 (73.3) 1.49 (0.66- 3.36) 
*** p < 0.001 
** p < 0.01 
* p < 0.05 
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PCL= Posttraumatic stress disorder Checklist - Civilian Version; PHQ-9 = Patient Health Questionnaire-9; GAD-7= Generalised Anxiety Disorder-7 Scale; 
AUDIT= Alcohol Use Disorder Identification Test, MH= any mental disorder, excluding alcohol misuse; mTBI= mild traumatic brain injury, cases with lack of 
consciousness (LOC)and those with symptoms associated with injury but not loss of consciousness separately 
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Table 4: Mental health, alcohol misuse and functional impairment prevalence and odds ratios at follow-up between intervention and control arms  
 
Outcome Trial arm Prevalance OR (unadjusted)1 OR (adjusted)2 OR (adjusted including baseline)3 
PCL Control 271 (11·5%) 1 1 1 
Intervention 432 (10·9%) 0·95 (0·77-1·17) 0·91 (0·74-1·10) 0·92 (0·75-1·14) 
PHQ-9 /GAD Control 150 (6·4%) 1 1 1 
Intervention 246 (6·2%) 0·98 (0·77-1·25) 0·88 (0·69-1·11) 0·91 (0·71-1·16) 
Any MH case Control 296 (12·5%) 1 1 1 
Intervention 492 (12·4%) 1·00 (0·82-1·21) 0·93 (0·77-1·12) 0·95 (0·79-1·16) 
AUDIT Control 288 (12·2%) 1 1 1 
Intervention 462 (11·6%) 0·94 (0·78-1.14) 0·91 (0·76-1·08) 0·88 (0·73-1·06) 
SF36 (case = 
“most of the 
time/all of 
the time”) 
Control 182 (7·8%) 1 1 1 
Intervention 295 (7·6%) 0·96 (0·78-1·19) 0·89 (0·72-1·10) 0·89 (0·72-1·09) 
Three or 
more PCS in 
those with 
mTBI 
Controls 29 (76.3%) 1 1  
Intervention 45 (64.3%) 0.56 (0.23- 1.37) 0.53 (0.21- 1.36)  
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PCL= posttraumatic stress disorder checklist civilian version; PHQ-9 = Patient Health Questionnaire-9; GAD-7= Generalised Anxiety Disorder-7 Scale; MH= 
any mental disorder, except alcohol misuse; AUDIT= Alcohol Use Disorder Identification Test; SF-36= Short Form-36. The definitions of caseness are given in 
the text. PHQ-15 was not included in the baseline questionnaire; PCS= post-concussion symptoms. 
  1 Using STATA “xtmelogit” command, with platoon as the nesting variable 
  2 Using STATA “xtmelogit” command, including service arm date of deployment, rank and age category as a fixed effect variables, with platoon as the 
nesting variable  
   3 Using STATA “xtmelogit” command, including baseline outcome (any mental health case for PCL and PHQ/GAD), service arm, deployment, rank and age 
category as fixed effect variables, with platoon as the nesting variable. 529 participants at follow up who were not assessed at baseline were excluded in 
this analysis. 
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Table 5 Effect of intervention on help–seeking and pharmaceutical use 
Outcome Trial arm Number 
affected (%) 
Odds ratio (95% 
CI) 
Adjusted odds ratio1 
(95% CI) 
Any health 
visit 
Control 1,500 (63·3) 1 1 
Intervention 2,410 (60·3) 0·87 (0·78–0·99)* 0·89 (0·79–1·01) 
Medical 
service usage 
Control 1,450 (61·2) 1 1 
Intervention 2,327 (58·2) 0·88 (0·78–0·99)* 0·89 (0·79–1·01) 
Welfare 
service usage 
Control 356 (15·0) 1 1 
Intervention 557 (13·9) 0·92 (0·77–1·09) 0·93 (0·79–1·10) 
Mental health 
service usage 
Control 318 (13·4) 1 1 
Intervention 496 (12·4) 0·91 (0·78–1·07) 0·92 (0·78–1·08) 
Antidepressant 
usage 
Control 67 (2·9) 1 1 
Intervention 129 (3·3) 1·15 (0·81–1·61) 1·08 (0·76–1·54) 
Sleeping pill 
usage 
Control 201 (8·6) 1 1 
Intervention 312 (8·0) 0·92 (0·75–1·13) 0·91 (0·74–1·11) 
* p< 0.05 
1 Adjusted for service, deployment, rank and age category
41 
 
Table 6: Prevalence and odds ratios in the follow up stage stratifying intervention arm by participant viewing tailored advice  
 
Outcome Trial arm Prevalence (%) OR (unadjusted for 
baseline caseness) 
OR (adjusted for baseline 
caseness)1 
PCL Control 247 (11·6) 1 1 
 Intervention, did not view advice 125 (10·3) 0·87 (0·67-1·14) 0·95 (0·73-1·24) 
 Intervention, viewed advice 283 (11·4) 1·00 (0·80-1·26) 0·91 (0·73-1·14) 
PHQ-9 /GAD Control 138 (6·5) 1 1 
 Intervention, did not view advice 66 (5·4) 0·83 (0·60-1·16) 0·89 (0·64-1·23) 
 Intervention, viewed advice 162 (6·6) 1·02 (0·78-1·33) 0·91 (0·70-1·19) 
Any MH case Control 271 (12·8) 1 1 
 Intervention, did not view advice 139 (11·4) 0·88 (0·69-1·14) 0·96 (0·75-1·23) 
 Intervention, viewed advice 324 (13·1) 1·05 (0·85-1·30) 0·95 (0·77-1·17) 
AUDIT Control 265 (12·5) 1 1 
 Intervention, did not view advice 143 (11·8) 0·92 (0·73-1·18) 0·96 (0·76-1·22) 
 Intervention, viewed advice 298 (12·1) 0·96 (0·78-1·18) 0·84 (0·69-1·02) (p = 0·084) 
SF-36 Control 166 (8·0) 1 1 
 Intervention, did not view advice 100 (8·5) 1·08 (0·82-1·42) 1·01 (0·77-1·32) 
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 Intervention, viewed advice 178 (7·3) 0·91 (0·72-1·15) 0·83 (0·66-1·04) (p = 0·10) 
 
PCL= posttraumatic stress disorder checklist civilian version; PHQ-9 = Patient Health Questionnaire-9; GAD-7= Generalised Anxiety Disorder-7 Scakle; MH= 
Any mental disorder, except alcohol misuse; AUDIT= Alcohol Use Disorder Identification Test; SF-36= Short Form-36. The definitions of caseness are given in 
the text. 
1 Using STATA “xtmelogit” command, including baseline outcome (any mental health case for PCL and PHQ/GAD), service arm, deployment, rank and age 
category as fixed effect variables, with platoon as the nesting variable 
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Table 7 Effect of viewing advice on seeking mental health services and pharmacological usage in the last 12 months 
Advice Trial arm No. with 
MH visit (%) 
AOR 1(95% CI) No. using anti-
depressants (%) 
AOR1 (95% CI) No. using 
hypnotics (%) 
AOR1 (95% CI) 
Would have received advice that there was no cause for concern regarding mental health 
Excluding 
alcohol 
misuse 
Control arm (n = 1,974) 228 (11·6) 1 40 (2·1) 1 151 (7·7) 1 
Viewed advice (n = 2,306) 259 (11·2) 0·94 (0·78–1·14) 64 (2·8) 1·30 (0·84–2·01) 170 (7·5) 0·94 (0·74–1·19) 
Did not view advice (n = 1,152) 130 (11·3) 0·93 (0·74–1·18) 26 (2·3) 1·04 (0·61–1·77) 72 (6·4) 0·79 (0·58–1·06) 
Including 
alcohol 
misuse 
Control arm (n = 1,844) 208 (11·3) 1 38 (2·1) 1 131 (7·2) 1 
Viewed advice (n = 2,120) 228 (10·8) 0·92 (0·75–1·12) 53 (2·5) 1·16 (0·74–1·82) 142 (6·8) 0·92 (0·72–1·19) 
Did not view advice (n = 1,097) 126 (11·5) 0·98 (0·77–1·24) 24 (2·2) 1.01 (0·59–1.72) 67 (6·3) 0·84 (0·62–1·15) 
Would have received advice to seek help after a positive result for a mental disorder  
Excluding 
alcohol 
misuse 
Control arm (n = 148) 53 (35·8) 1 21 (14·2) 1 34 (23·9) 1 
Viewed advice (n = 200) 70 (35·0) 1·06 (0·67–1·67) 27 (13·9) 0·93 (0·49–1·76) 43 (22·2) 1·01 (0·57–1·79) 
Did not view advice (n = 49) 12 (24·5) 0·55 (0·26–1·16)  7 (14·9) 1·12 (0·43–2·90) 16 (34·0) 1·80 (0·80–4·03) 
Including 
alcohol 
misuse 
Control arm (n = 278) 73 (26·3) 1 23 (8·4) 1 54 (19·6) 1 
Viewed advice (n = 386) 
101 (26·2) 1·05 (0·73–1·50) 38 (10·0) 1·12 (0·64–1·98) 71 (18·7) 0·92 (0·61–1·39) 
Did not view advice (n = 104) 16 (15·4) 0·50 (0·27–0·92)* 9 (8·9) 1·05 (0·45–2·44) 21 (20·8) 1·02 (0·56–1·83) 
1 Adjusted for service, deployment, rank and age category
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Research in context 
Evidence before this study 
On completion of the study in January 2016, we carried out search of Medline, Embase and 
Psychoinfo to identify any studies on post-deployment screening with the terms  “mental disorders”, 
“psychological illness”, “mental health”, “posttraumatic stress disorder”, “PTSD”, “depression”, 
“anxiety”,” alcohol misuse”, or “alcoholism”, and “post-deployment”, “screening”, and “RCT”, 
“randomised controlled trial” or” effectiveness” which yielded 11 publications, five of them 
duplicates, none of them relevant to the aim of this study. We changed the term “post-deployment” 
for “military”, “armed forces”, “army”, “navy”, or “air force” to make it less restrictive. The search 
provided 68 publications, 16 duplicates, none of which were considered relevant to our study. A 
similar search, including one of the terms ‘“help-seeking”, “treatment seeking”, “health service 
provision” or “service use”,’ was carried out for the effects on help-seeking in April 2016. There were 
only 2 papers fulfilling these search criteria, neither of which were relevant to this study. Post-
deployment screening for mental disorders was not a consideration in the military until after the 
Gulf War in 1991. Post-deployment screening for mental disorders was mandated by the US 
Congress in 1998 and since 2003, screening was implemented among US forces and developed and 
modified during the Iraq and Afghanistan conflicts.  
Added value of this study 
This is the only RCT study of post-deployment screening for mental disorders that has been carried 
out. The US, Canada, Australia and Holland have implemented post-deployment screening already 
and are unable to carry out an RCT without ceasing their current programme which is politically 
impossible in those countries. The conditions explored in our study are those usually assessed in any 
screening programmes for mental disorders. The results of our study should help to develop or 
modify models of post-deployment screening programmes implemented in countries where 
screening is mandatory. Armed Forces which are considering the introduction of a post-deployment 
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screening could benefit from the findings of our study. It should be also helpful to occupations facing 
high risk of exposure to trauma such as emergency services and media. 
Implications of all the available evidence 
Our study demonstrated that post-deployment screening based on tailored advice is not effective in 
reducing the prevalence of mental disorders. This is consistent with the finding that tailored advice 
does not increase help-seeking. This is not entirely surprising given the well-known findings that in 
most studies that around half of those with a mental disorder do not seek health-care, that many of 
those who seek health care do not go beyond the initial assessment and that a large percentage who 
initiate treatment do not finish it. Our study demonstrated that as many as a third of those who 
were given the opportunity to receive tailored advice chose not to see it. Of course, screening 
programmes and procedures will vary between countries. It is for each country to assess whether 
differences in detail between their programmes and our study could make a difference to the results 
presented here. At the very least, countries which have implemented post-deployment screening 
should have a monitoring system in place to evaluate the psychological and financial impact of their 
programmes.  
 
Figure 1 Decision pathway related to the intervention arm of the trial. Control arm received 
the same assessment but only general advice (see text).  
 
Short instrument 
thresholds exceeded? 
Scores any threshold 
for full instrument: 
PCL: 50+ 
PHQ-9: 5+ on Qs 3-9 
GAD: 15+ 
AUDIT: 5+ on alcohol 
dependence and/or 
10+ on alcohol harm 
Recommended 
to consult 
primary care 
Scores any threshold 
for full instrument: 
PCL: 40-49 
PHQ-9: 2-4 on Qs 3-9 
GAD: 10-14 
AUDIT: 20+ 
YES* 
YES 
Recommended 
to consult non-
medical care 
YES 
NO 
No support 
recommended 
NO 
NO 
* Respondents only directed to full instruments for which 
they fulfilled the threshold on the short instrument 
PCL= Posttraumatic stress disorder Checklist = Civilian 
version; PGQ-9= Patient Health Questionnaire-9; GAD= 
Generalised Anxiety Disorder; AUDIT= Alcohol Use 
Disorder Identification Test 
Figure 1
Figure 2 Participants, percentage rates and numbers leaving the study at each stage by 
arm of the trial. Percentages estimated from total service personnel in each arm at 
enrolment 
 
  
 
434 platoons 
sampled into trial 
274 platoons allocated 
to intervention  
(n = 6,350) 
160 platoons 
allocated to control 
(n = 3,840) 
Enrolment 
Allocation 
Received intervention 
questionnaire  
(n = 5,577 (87·8%)) 
3 deceased 
770 did not 
receive 
questionnaire 
 Received control 
questionnaire  
(n = 3,149 (82·0%)) 
3 deceased 
688 did not 
receive 
questionnaire 
 
Follow-Up 
3,996 (62·9%) 
responses at follow-up 
(includes 288 non-
responders at baseline)
   
2,369 (61·7%) 
responses at follow-up 
(includes 241 non-
responders at baseline) 
3 died 
158 had no 
contact details 
398 declined 
1,310 did not 
respond 
 
1 died 
106 had no 
contact details 
197 declined 
717 did not 
respond 
 
Analysis 
3,996 analysed (0 
excluded from 
analysis)  
2,369 analysed (0 
excluded from 
analysis)  
Figure 2
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CONSORT 2010 checklist of information to include when reporting a randomised trial* 
 
Section/Topic 
Item 
No Checklist item 
Reported 
on page No 
Title and abstract 
 1a Identification as a randomised trial in the title Yes 
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) Yes 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale Yes 
2b Specific objectives or hypotheses Yes 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio Yes 
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons Yes 
Participants 4a Eligibility criteria for participants Yes 
4b Settings and locations where the data were collected Yes 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were 
actually administered 
Yes 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they 
were assessed 
Yes 
6b Any changes to trial outcomes after the trial commenced, with reasons None 
Sample size 7a How sample size was determined Yes 
7b When applicable, explanation of any interim analyses and stopping guidelines Yes 
Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation sequence Yes 
8b Type of randomisation; details of any restriction (such as blocking and block size) Yes 
 Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until interventions were assigned 
Yes 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to 
interventions 
Yes 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those Yes 
Papers in press and other supporting documentation
CONSORT 2010 checklist  Page 2 
assessing outcomes) and how 
11b If relevant, description of the similarity of interventions Not 
necessary 
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes Yes 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses Yes 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and 
were analysed for the primary outcome 
Yes 
13b For each group, losses and exclusions after randomisation, together with reasons Yes 
Recruitment 14a Dates defining the periods of recruitment and follow-up Yes 
14b Why the trial ended or was stopped Not 
necessary 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group Yes 
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was 
by original assigned groups 
Yes 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its 
precision (such as 95% confidence interval) 
Only primary 
outcomes 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended Not 
necessary 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory 
Yes 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) Yes 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses Yes 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings Yes 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence Yes 
Other information  
Registration 23 Registration number and name of trial registry Yes 
Protocol 24 Where the full trial protocol can be accessed, if available Submitted to 
the Lancet 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders Yes 
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*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also 
recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. 
Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org. 
